Table III.
Adjusted hazard ratio and 95% confidence intervals for melanoma-specific survival of different racial/ethnicity groups compared with non-Hispanic whites in the Surveillance, Epidemiology, and End Results cohort and across 3 diagnostic time periods for different stages for cutaneous melanoma
| <2000 |
2000–2009 |
≥2010 |
||||
|---|---|---|---|---|---|---|
| Race | aHR (95% CI) for MSS | aHR (95% CI) for MSS | P for interaction | aHR (95% CI) for MSS | P for interaction | |
| Localized stage* | ||||||
| Hispanic | 1.05 (0.90–1.24) | 1.44 (1.26–1.66) | .004 | 1.54 (1.21–1.96) | .010 | |
| NHB | 1.49 (1.12–1.98) | 1.92 (1.44–2.57) | .21 | 4.08 (2.70–6.16) | <.001 | |
| NHAPI | 1.19 (0.90–1.58) | 1.46 (1.09–1.94) | .33 | 2.19 (1.41–3.40) | .023 | |
| NHAIAN | 0.79 (0.42–1.46) | 1.20 (0.68–2.12) | .32 | 2.14 (1.02–4.50) | .042 | |
| Regional stage* | ||||||
| Hispanic | 1.01 (0.83–1.22) | 1.32 (1.17–1.49) | .021 | 1.56 (1.30–1.87) | .001 | |
| NHB | 1.62 (1.22–2.15) | 1.49 (1.19–1.86) | .64 | 1.74 (1.24–2.45) | .76 | |
| NHAPI | 1.17 (0.88–1.56) | 1.26 (1.02–1.56) | .69 | 1.28 (0.85–1.93) | .73 | |
| NHAIAN | 2.30 (1.27–4.16) | 1.19 (0.75–1.90) | .087 | 2.86 (1.66–4.94) | .60 | |
| Distant stage* | ||||||
| Hispanic | 0.83 (0.66–1.05) | 1.06 (0.92–1.23) | .081 | 1.17 (0.99–1.38) | .019 | |
| NHB | 1.33 (1.00–1.76) | 0.78 (0.60–1.01) | .007 | 1.01 (0.74–1.39) | .21 | |
| NHAPI | 1.18 (0.86–1.62) | 1.03 (0.81–1.32) | .51 | 1.68 (1.27–2.23) | .10 | |
| NHAIAN | 1.25 (0.59–2.62) | 0.64 (0.31–1.35) | .21 | 0.77 (0.37–1.61) | .36 | |
| All stages* | ||||||
| Hispanic | 0.95 (0.86–1.06) | 1.35 (1.25–1.46) | <.001 | 1.56 (1.41–1.73) | <.001 | |
| NHB | 1.40 (1.20–1.64) | 1.30 (1.13–1.50) | .48 | 1.87 (1.54–2.28) | .024 | |
| NHAPI | 1.20 (1.02–1.41) | 1.32 (1.15–1.51) | .39 | 1.97 (1.62–2.40) | <.001 | |
| NHAIAN | 1.12 (0.78–1.60) | 1.15 (0.85–1.55) | .92 | 1.61 (1.12–2.32) | .16 | |
aHR, Adjusted hazard ratio; CI, confidence interval; MSS, melanoma-specific survival; NHAIAN, non-Hispanic American Indian/Alaska Native; NHAPI, non-Hispanic Asian or Pacific Islander; NHB, non-Hispanic black; NHW, non-Hispanic white.
For each of the 4 models (localized stage, regional stage, distant stage, and all stages), the adjusted HRs for MSS and P values were calculated from Cox proportional hazard models with race, year of diagnosis, and the interaction terms, adjusting for age, gender, primary site, histologic subtype, and stage. P values in 2000–2009 showed significance comparing the adjusted HRs to NHWs for melanomas diagnosed in 2000–2009 and those for melanomas diagnosed <2000. P values in ≥2010 showed significance comparing the adjusted HRs to NHWs for melanomas diagnosed in ≥2010 and those for melanomas diagnosed before 2000.